Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
AU Stock MarketDetailed Quotes
Radiopharm Theranostics Ltd (RADO)
- 0.001
- 0.0000.00%
20min DelayMarket Closed Feb 4 13:12 AET
3.54MMarket Cap0.00P/E (Static)
0.000High0.000Low0Volume0.000Open0.001Prev Close0.00Turnover0.00452wk High0.00%Turnover Ratio3.54BShares0.00152wk Low--EPS TTM2.37MFloat Cap0.070Historical High0.00P/E (Static)2.37BShs Float0.001Historical Low--EPS LYR0.00%Range %--Dividend TTM0.00P/B1Lot Size--Div Yield TTM
Radiopharm Theranostics Ltd (RADO) Income Statement
Quarterly+Annual
YOY
| (FY)Jun 30, 2025 | (FY)Jun 30, 2024 | (FY)Jun 30, 2023 | (FY)Jun 30, 2022 | |
|---|---|---|---|---|
| Total revenue | 1,114.27%3.63M | 2.35%299.23K | 3,210.60%292.36K | 8.83K |
| Operating revenue | 1,114.27%3.63M | 2.35%299.23K | 3,210.60%292.36K | --8.83K |
| Cost of revenue | 3.59M | 0 | 0 | |
| Gross profit | -86.87%39.28K | 2.35%299.23K | 3,210.60%292.36K | 8.83K |
| Operating expense | -7.45%34.68M | 17.17%37.47M | 60.52%31.98M | 19.93M |
| Selling and administrative expenses | 5.45%16.53M | 2.68%15.67M | 36.12%15.26M | --11.21M |
| -General and administrative expense | 5.45%16.53M | 2.68%15.67M | 36.12%15.26M | --11.21M |
| Research and development costs | 19.18%27.52M | 2.01%23.09M | 448.68%22.63M | --4.12M |
| Depreciation amortization depletion | -2.69%7.33K | 14.97%7.53K | -99.78%6.55K | --2.98M |
| -Depreciation and amortization | -2.69%7.33K | 14.97%7.53K | -99.78%6.55K | --2.98M |
| Other operating expenses | -624.80%-9.37M | 78.16%-1.29M | -468.28%-5.92M | --1.61M |
| Operating profit | 6.81%-34.64M | -17.30%-37.17M | -59.12%-31.69M | -19.92M |
| Net non-operating interest income (expenses) | 247.60%333.11K | -482.88%-225.69K | 100.63%58.94K | -9.35M |
| Non-operating interest income | 1,659.36%888.2K | -65.19%50.48K | --145.04K | ---- |
| Non-operating interest expense | -89.84%65.3K | 646.75%642.89K | -99.08%86.09K | --9.35M |
| Total other finance cost | 233.56%489.79K | ---366.72K | ---- | ---- |
| Other net income (expenses) | 62.39%-3.93M | -255.37%-10.45M | -186.00%-2.94M | -1.03M |
| Gain on sale of security | 45.47%138.14K | 136.91%94.96K | 74.99%-257.25K | ---1.03M |
| Special income (charges) | 61.42%-4.07M | -292.96%-10.55M | ---2.68M | ---- |
| -Less:Restructuring and mergern&acquisition | -54.07%4.07M | 230.08%8.86M | --2.68M | ---- |
| -Less:Impairment of capital assets | ---- | -52.29%1.48M | --3.1M | ---- |
| -Gain on sale of property,plant,equipment | --0 | ---1.69M | --0 | ---- |
| Other non-operating income (expenses) | ---- | -227.89%-7.57M | --5.92M | ---- |
| Income before tax | 20.09%-38.24M | -38.41%-47.85M | -14.12%-34.57M | -30.29M |
| Income tax | 7.19%103.29K | 153.56%96.36K | -14.40%38.01K | 44.4K |
| Earnings from equity interest net of tax | ||||
| Net income | 20.04%-38.34M | -38.54%-47.95M | -14.08%-34.61M | -30.34M |
| Net income continuous operations | 20.04%-38.34M | -38.54%-47.95M | -14.08%-34.61M | ---30.34M |
| Noncontrolling interests | ||||
| Net income attributable to the company | 20.04%-38.34M | -38.54%-47.95M | -14.08%-34.61M | -30.34M |
| Preferred stock dividends | ||||
| Other under preferred stock dividend | ||||
| Net income attributable to common stockholders | 20.04%-38.34M | -38.54%-47.95M | -14.08%-34.61M | -30.34M |
| Diluted earnings per share | ||||
| Basic earnings per share | ||||
| Dividend per share | ||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- |
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
According to Axios, on Sunday local time, Trump rejected Iran's latest ceasefire proposal, prompting a sharp response from Iran: no one woul
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm